Inebilizumab/pembrolizumabAcute neuromyelitis optica spectrum disorder attack and lack of efficacy: case report

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-023-43221-7
中图分类号
学科分类号
摘要
引用
收藏
页码:253 / 253
相关论文
共 50 条
  • [1] Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
    Lehrieder, Dominik
    Zapantis, Nikolaos
    Pham, Mirko
    Schuhmann, Michael Klaus
    Haarmann, Axel
    [J]. FRONTIERS IN NEUROLOGY, 2023, 14
  • [2] Attack Diagnoses and Adjudication in a Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
    Bennett, J. L.
    Wingerchuk, D.
    Green, A.
    Greenberg, B.
    Cutter, G.
    She, D.
    Smith, M.
    Katz, E.
    Cree, B. A.
    Weinshenker, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 143 - 143
  • [4] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    [J]. NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [5] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Tina Nie
    Hannah A. Blair
    [J]. CNS Drugs, 2022, 36 : 1133 - 1141
  • [6] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Nie, Tina
    Blair, Hannah A.
    [J]. CNS DRUGS, 2022, 36 (10) : 1133 - 1141
  • [7] A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report
    Chen, Xuefen
    Shi, Ziyan
    Wang, Rui
    Zhou, Hongyu
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [8] Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Tina Nie
    Hannah A. Blair
    [J]. CNS Drugs, 2022, 36 : 1239 - 1239
  • [9] Safety, Efficacy and Pharmacokinetics of Inebilizumab in African Americans with Neuromyelitis Optica Spectrum Disorder
    Bernitsas, E.
    Cimbora, D.
    Dinh, Q.
    Yan, L.
    She, D.
    Katz, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 149 - 150